TY - JOUR
T1 - Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
AU - Kronenberg, Florian
AU - Mora, Samia
AU - Stroes, Erik S. G.
AU - Ference, Brian A.
AU - Arsenault, Benoit J.
AU - Berglund, Lars
AU - Dweck, Marc R.
AU - Koschinsky, Marlys L.
AU - Lambert, Gilles
AU - Mach, François
AU - McNeal, Catherine J.
AU - Moriarty, Patrick M.
AU - Natarajan, Pradeep
AU - Nordestgaard, B. rge G.
AU - Parhofer, Klaus G.
AU - Virani, Salim S.
AU - von Eckardstein, Arnold
AU - Watts, Gerald F.
AU - Stock, Jane K.
AU - Ray, Kausik K.
AU - Tokgözoğlu, Lale S.
AU - Catapano, Alberico L.
N1 - Publisher Copyright: © 2023 The Authors
PY - 2023/6
Y1 - 2023/6
N2 - In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: "Why should I measure Lp(a) if I can't lower it?". Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.
AB - In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: "Why should I measure Lp(a) if I can't lower it?". Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.
KW - Atherosclerotic cardiovascular disease
KW - Genetic risk
KW - Risk calculator
KW - Risk factor management
KW - lipoprotein(a)
UR - http://www.scopus.com/inward/record.url?scp=85159204299&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.atherosclerosis.2023.04.012
DO - https://doi.org/10.1016/j.atherosclerosis.2023.04.012
M3 - Review article
C2 - 37188555
SN - 0021-9150
VL - 374
SP - 107
EP - 120
JO - Atherosclerosis
JF - Atherosclerosis
ER -